REG - Eco Animal Health Gp - New Marketing Authorisations for Aivlosin in China

ECO Animal HealthAnnouncement

23/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220223:nRSW4879Ca&default-theme=true

RNS Number : 4879C  Eco Animal Health Group PLC  23 February 2022

23 February 2022

 

ECO Animal Health Group plc

("the Company" or the "Group")

(AIM: EAH)

 

ECO RECIEVES TWO NEW MARKETING AUTHORISATIONS FOR AIVLOSIN® IN CHINA

ECO Animal Health Group plc is pleased to announce that its subsidiary ECO
Animal Health Limited ("ECO") has received two marketing authorisations from
the Ministry of Agriculture and Rural Affairs ("MOA") of the People's Republic
of China for the use of Aivlosin® Water Soluble Granules ("WSG"). Aivlosin®
is used for the treatment of a variety of economically important respiratory
and enteric (gut) diseases in pigs and poultry.

The first approval allows ECO to market Aivlosin® WSG in China for the
treatment of respiratory disease caused by Mycoplasma and other sensitive
bacteria in chickens laying eggs for human consumption and breeding chickens.
Aivlosin® is the first antimicrobial to be licensed by the Chinese MOA for
laying birds with a zero day drug withdrawal period for eggs.

The second Aivlosin® WSG approval is for swine respiratory disease ("SRD")
adding three important bacterial respiratory pathogens of swine, Haemophilus
parasuis, Pasteurella multocida, and Streptococcus suis to the existing
Mycoplasma hyopneumoniae registration. SRD occurs worldwide and causes major
economic losses to the pig industry due to mortality, reduction in growth
rates and decreased feed efficiency.

Marc Loomes, CEO, commented: "We are delighted to receive these important
marketing authorisations for Aivlosin® WSG. China is the world's largest
producer of table eggs and accounts for more than a third of the world's
laying birds. Aivlosin® is the first antimicrobial registered for use in
laying hens producing eggs for human consumption, with a zero day egg
withdrawal period.  This will enable ECO to target a new sector, the
commercial egg producer, where Mycoplasmosis can cause significant economic
losses.  China is also the largest pork producing country in the world and
broader product label claims in the key SRD segment will serve our  business
well as the market recovers in the future."

 

The information contained within this announcement is deemed by the Group to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 ("MAR") as it forms part of United Kingdom domestic law by
virtue of the European Union (Withdrawal) Act 2018. Upon the publication of
this announcement via a Regulatory Information Service ("RIS"), this inside
information is now considered to be in the public domain.

 

 

Contacts:

                                                                020 8447 8899

 ECO Animal Health Group plc

 Marc Loomes (CEO)

 Christopher Wilks (CFO)

 IFC Advisory                                                   020 3934 6630

 Graham Herring

 Zach Cohen

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Mark Taylor

 George Tzimas

 Peel Hunt LLP (Joint Broker)                                   020 7418 8900

 James Steel

 Dr Christopher Golden

 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Alex Penney

 Carlo Spingardi

 Equity Developments                                            020 7065 2692

 Hannah Crowe

 Matt Evans

 

 

About ECO Animal Health

 

ECO Animal Health Group plc ("ECO" or "the Group") researches, develops and
commercialises products for livestock. Our business strategy is to generate
shareholder value by achieving the maximum sales potential from the existing
product portfolio whilst investing in Research and Development ("R&D") for
new products, particularly vaccines, and seeking to in-license new products.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCTTMLTMTTTBFT